% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

wilderguide 133 posts  |  Last Activity: Aug 24, 2016 5:54 PM Member since: Jan 13, 2011
  • Reply to

    "Potential mechanisms"

    by wilderguide Jul 19, 2016 9:18 AM
    wilderguide wilderguide Jul 20, 2016 10:56 AM Flag

    "Perhaps you're nothing but a Perrin cheerleader..."
    Just a fan of the science, which is actually faring well in early scrutiny. If the pace of progress is a bit slow for you, I recommend that you invest in something a bit more fantastical - perhaps Disney is more your style.

  • wilderguide by wilderguide Jul 20, 2016 8:51 AM Flag

    Lots in place, particularly in RCC follow-up...
    814P, 815P, 816P, 818P. Updated QOL reporting could be a sales factor...
    Apolo studies in mUC and in Cabo combo w/ Nivo will also update...
    See also Cabo in post-doxorubicin treated HGUS...
    Looks like everybody's moving to IV...
    Guess I might as well too...

  • Reply to

    "Potential mechanisms"

    by wilderguide Jul 19, 2016 9:18 AM
    wilderguide wilderguide Jul 19, 2016 8:06 PM Flag

    "Thanks for posting..."
    De nada. This has become a troubled MB. The most persistent posters are also those with an agenda obviously counter to the long thesis. Cynicism, contempt, and misinformation from Thrope, biotrader, and others makes for difficulty in sharing good info. I'd like to change that...

  • Reply to

    "Potential mechanisms"

    by wilderguide Jul 19, 2016 9:18 AM
    wilderguide wilderguide Jul 19, 2016 12:30 PM Flag

    I believe what follows is previously unpublished, and has not yet been PR'd by anyone.
    "RESULTS: There were no NSS-related serious safety events. On screening MRI, patients typically exhibited spinal cord compression and edema. Three of 5 patients had intraspinal hemorrhage. Based on central neuroradiology review of pre- and postoperative MRI scans through 6 months, none of the patients had definite cyst formation defined by T2 and T1 changes. By 6 months, 3 of 5 patients had converted from Abbreviated Injury Scale (AIS) A to AIS B(2) or C(1). One patient gained 10 points of hip and knee function by 6 months, with additional improvement and new ankle function at 12 months (increased motor score of 8). One patient converted from AIS A to B at 6 months, a late-occurring conversion that is extremely rare.

    CONCLUSION: This study represents the first use of the intraspinal NSS in patients with complete thoracic SCI. By 6 months, the low incidence of cyst formation with preservation of some intralesion internal architecture is consistent with preclinical results in which the resorbable NSS was replaced by a matrix of axon-containing remodeled tissue. The possibility of ongoing neural regeneration may contribute to the high incidence of AIS conversion and sustained period of neurological recovery."

  • wilderguide by wilderguide Jul 19, 2016 9:18 AM Flag

    Published in Neurosurgery, August 2016
    "High Abbreviated Injury Scale Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete Abbreviated Injury Scale A Spinal Cord Injury: Potential Mechanisms."
    Theodore N, et al...

  • wilderguide by wilderguide Jul 19, 2016 8:42 AM Flag

    From the CHMP agenda for this week's meeting, published earlier today:
    "3.1.1. cabozantinib - EMEA/H/C/004163
    Accelerated assessment
    treatment of advanced renal cell carcinoma (RCC) Scope: Opinion
    Action: For adoption"
    Hard to believe no announcement comes this week...
    But if no opinion is proffered, the CHMP does not meet again till Sept...

  • wilderguide by wilderguide Jul 17, 2016 7:13 AM Flag

    J Haemotology Awan, et al....6/13/2016
    "Of 35 efficacy-evaluable patients, four (11·4%) achieved complete response and 13 (37·1%) achieved partial response. Voxtalisib, in combination with rituximab or rituximab+bendamustine, demonstrated an acceptable safety profile and encouraging anti-tumour activity in relapsed or refractory B-cell malignancies."
    Joe: I had to split earlier than expected. Next time...

  • $$$$
    "CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in DOCA/salt-induced hypertensive rats"...K Arai, et al JPET July 6, 2016
    A couple of interesting experiments reported here, clearly indicating amelioration of kidney injury independent of activity in modifying systolic blood pressure. Something very novel going on here, and I look forward to the first clinical reporting of human responses. Full free text available at PMC.

  • Reply to

    The last date EXEL reached this price

    by captainhymanshocker Jul 11, 2016 1:51 PM
    wilderguide wilderguide Jul 11, 2016 2:53 PM Flag

    "Muskrat candlelight", written by Willis Alan Ramsey...
    One of my earliest favorite songwriters...
    He first recorded this tune in 1971, on his only album - recorded at the age of 19. He still tours, and is definitely worth the price of a ticket. Peace, out...

  • Reply to

    Sutent vs Cabometyx

    by tevanj Jul 10, 2016 9:52 AM
    wilderguide wilderguide Jul 11, 2016 7:37 AM Flag

    "...will Cabometryx replace Stutent or will both continue to be used?"
    I think we'll need to wait for data presentations at ESMO. Sutent's long tenure as SOC may prove a tough nut to crack, so CABOSUN data will be closely scrutinized by the RCC community. Pfizer's S-TRAC data is also promised at this venue, and the use of a TKI in early stage post-surgical disease may actually set a new standard of prophylactic adjuvant care. To my knowledge, Cabo is untested in such early stage disease, but there is compelling rationale to date suggesting Cabo superiority to sunitinib, so a future comparison in early stage disease may be inevitable. Lots to consider moving forward, and the RCC KOLs will have a field day with ESMO data as this all shakes out. Your question will likely be revisited on this MB many times in the coming months as those thought leaders weigh in after ESMO.

  • wilderguide wilderguide Jul 10, 2016 3:23 PM Flag

    "Then again your 'so called posters' comment was kinda douchey...
    My apologies to all for my caustic attempt at humor, but I was mainly responding to the smart-alecky approach to posting such obviously misdirected, misinterpreted info without proper confirmation.
    Sometimes I'm a very bad boy...

  • wilderguide wilderguide Jul 10, 2016 4:42 AM Flag

    From Wikipedia:
    "Exel is a supply chain and logistics company operating in North America and Europe. Exel is wholly owned by the German firm Deutsche Post DHL. It reports annual revenues of about $4.2 billion."

    Hi RPC... The so-called "smart posters" on this message board have united, taken up a collection, and contracted with the supply and logistics company - Exel, Inc - to send you a brain. Delivery expected next week. Please use it well. Have you considered investing in that fruit company, Apple? Can I show you some oceanfront property in Oklahoma? Perhaps an avocado orchard in Alaska? Maybe a dolphin farm in downtown Detroit? A hedgehog haberdashery in Hoboken? A dingleberry dump in Duluth?...
    Good luck with all your investments...

  • $$$$
    "CBT profiles of cabozantinib approved for advanced renal cell carcinomas"
    Published in Cell Biology & Toxicology, Xiangdong Wang, 06 July 2016
    Good discussion of Cabo potential based upon its known targeted profile and it's theoretic interactivity with un-targeted pathways, kinases, and other cell-signaling mechanisms. For the past several years, Wang has published extensively on MET inhibition, and - for my money - is one of the leading authorities on MET/VEGF combination therapy. I think this editorial speaks toward his optimism for Cabo potential outside RCC, and bodes well for shareholders. Good read...

  • $$$$
    Published 6/28/2106 European Journal of Cancer, Garber, et al...
    "BRAF inhibitors like dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib for BRAF mutated patients should be offered as first or second line treatment. "

  • $$$$
    "Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer."
    Chong, et al... CCR 7/1/2016
    More reinforcement for cabozantinib in post-crizotinib treatment resistant lung cancer...
    Research and publication courtesy of Mass Gen, Harvard, Dana-Farber CC...
    Pasi Janne is listed as corresponding author...

  • wilderguide wilderguide Jul 2, 2016 11:07 AM Flag

    "The surge in volume yesterday and today..what could be the resaons?"
    There's obviously a lot we don't know... To put an edge on that statement, consider that Merck paid out a $5M milestone in Q1 2016 for its XL-499 collaboration. I queried IR about that program, and they declined to provide further color. The treatment spaces surrounding EXEL's ROR agonist program is also apparently heating up. As recently as Jan2016, Celgene licensed with Lycera for their ROR agonist immunotherapeutic program. LXR modulation is seeing increased publication as a compelling dermal disease treatment. EXEL is one of 4 major patent holders in this space, along with Abbott, Boehringer, and Calcimedica. FWIW - the EXEL patent filing in the LXR modulation space is the earliest on record. All early stage stuff, but increasingly viable with loads of current interest. Added to what we DO know regarding clinical potentials of Cabo, Cobi, and XL-888...
    There's as yet a lot of potential flying beneath the radar.
    Next ER update could prove quite entertaining.
    Congrats & GLTA. Enjoy your holiday...

  • Reply to

    Another scaffold study?

    by imamisanthrope Jul 1, 2016 3:33 PM
    wilderguide wilderguide Jul 1, 2016 5:33 PM Flag

    "Anybody walkin' yet, jagoff?"
    What a frickin' dooshwaddle...

  • wilderguide wilderguide Jun 30, 2016 1:49 PM Flag

    "Anybody walking yet...?"
    Walking would be a lot to ask for, and is not even in the same of expectations of the INSPIRE study. All that is necessary for HDE consideration is for the scaffold to convert 25% of a 20-patient recruitment. The trial is better than 2/3 of its way to a successful outcome, based upon target endpoints. What don't you get?

  • wilderguide wilderguide Jun 30, 2016 1:21 PM Flag

    "...shoddy performance..."
    Re: Beckers: 3 out of the first 5 patients have converted - others have displayed improvement. This same patient group, if left untreated,, only 16% convert in the first six months. Where's all this shoddy performance?
    You on the right MB? Wouldn't you be best off trading REITs?

  • wilderguide wilderguide Jun 30, 2016 10:53 AM Flag

    Seems like you noodleheads got nothing better to do - why not help out?
    Take one for the team. You could start by practicing back flips into the shallow end of your swimming pool. Maybe practice your high dive into a bucket of water...maybe see who can do the best "dead German soldier" off the top step of an 8ft ladder. Encourage the wife, kids, & neighbors to participate.
    It don't hurt so bad if yer makin' money off the results, does it?
    Wishin' harm on others...y'all need a change o' scenery...

10.96+0.05(+0.46%)Aug 26 4:00 PMEDT